With NJ Transit engineers on strike, here's what commuters need to know
A labor dispute between NJ Transit's locomotive engineers and the Garden State transit agency's management became New Jersey's first rail strike in more than 40 years as of Friday morning at 12:01 a.m. Eastern time.
Here's what commuters need to know:
As of a minute past midnight Friday, members of the Brotherhood of Locomotive Engineers and Trainmen — the union representing about 450 Garden State train engineers — walked off the job after BLET and NJ Transit management spent the day at the bargaining table in Newark on Thursday. The move impacts more than 350,000 commuters.
The disagreement comes down to wages.
NJ Transit engineers say they want parity with their colleagues at Long Island Rail Road and Metro-North, while management says that will lead every other union to ask for similar raises and endanger the financial security of the agency.
The MTA's Long Island Rail Road, where an engineer's hourly rate is $49.92, is the busiest of the nation's commuter railroads. Metro-North, in second place, pays $57.20 an hour.
Currently, NJ Transit engineers, who operate the nation's third busiest commuter system, start at $39.78 an hour — a figure that includes the NJ Transit engineers who operate within New York state on Metro-North's west-of-Hudson lines.
The BLET and NJ Transit reached a tentative contract agreement in March, after working without a contract since the start of 2020.
That agreement, according to NJ Transit President Kris Kolluri, included a pay bump that would have seen BLET members earn $49.82 an hour by the summer. But the contract was overwhelmingly rejected by the union rank-and-file, who voted it down by 87%.
But LIRR engineers are in the midst of their own negotiations, and BLET's New Jersey boss, Tom Haas, has said any parity with the Long Island engineers would therefore be fleeting.
No.
NJ Transit is hoping to offer other ways to travel.
The state's buses — whose unionized drivers just reached a contract agreement with NJ Transit this month — will still be running, and NJ Transit management is hoping to use them to ease the pain.
The transit agency will run 'park and ride' routes, with NJT buses taking people from Secaucus Junction to the Port Authority Bus Terminal in Midtown Manhattan, from the Hamilton rail station to Newark Penn's PATH station, and from the Woodbridge Mall to the Harrison PATH station.
Private contractor Academy Bus will also operate a park-and-ride from the PNC Bank Arts Center in Holmdel to the Port Authority Bus Terminal — but Academy will not be accepting NJ Transit tickets.
Bus service will be increased on a series of regular New York-bound routes, and NJ Transit rail tickets to or from New York, Newark or Hoboken will be cross-honored on NJ Transit buses and the Hudson-Bergen Light Rail.
It's unclear. NJ Transit rail strikes are a rarity.
An NJ Transit rail dispute seemed headed for a strike back in 2016, but eleventh-hour negotiations averted a work stoppage.
The Garden State's engineers last hit the picket lines in 1983, when they struck for 34 days.
_____

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
an hour ago
- Associated Press
IBTA DEADLINE NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Ibotta, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm
New York, New York--(Newsfile Corp. - June 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the 'Registration Statement') issued in connection with Ibotta's April 18, 2024 initial public offering (the 'IPO'); or (2) between April 18, 2024 and February 26, 2025, inclusive (the 'Class Period'), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ibotta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Ibotta class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, in the Registration Statement and/or throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Ibotta did not properly warn investors of the risk concerning Ibotta's contract with Kroger; (2) Ibotta's data measurement system did not provide accurate, precise, and real time client campaign and consumer data measurement; (3) Ibotta's business mix had shifted and was generating less revenue; and (4) Ibotta had 'exhausted' its clients' budgets, negatively impacting fourth quarter 2024 revenue and expected first quarter 2025 revenue. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Ibotta action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit


Associated Press
an hour ago
- Associated Press
ZBIO FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm
NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the 'Registration Statement') issued in connection with Zenas BioPharma's September 2024 initial public offering ('IPO' or the 'Offering'), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Zenas BioPharma class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Zenas BioPharma action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]

Associated Press
an hour ago
- Associated Press
BBAI DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages BigBear.ai Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - June 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Holdings, Inc. (NYSE: BBAI) between March 31, 2022 and March 25, 2025, both dates inclusive (the 'Class Period'), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) maintained deficient accounting review policies related to the reporting and disclosure of certain non-routine, unusual, or complex transactions; (2) as a result, incorrectly determined that the conversion option within the 2026 Convertible Notes qualified for the derivative scope exception under Accounting Standards Codification ('ASC') 815-40 and failed to bifurcate the conversion option as required by ASC 815-15; (3) accordingly, had improperly accounted for the 2026 Convertible Notes; (4) the foregoing error caused to misstate various items in several of previously issued financial statements; (5) as a result, these financial statements were inaccurate and would likely need to be restated; (6) would require extra time and expense to correct the inaccurate financial statements, thereby increasing the risk that would be unable to timely file certain financial reports with the SEC; and (7) as a result, public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit